📊 Business

R&D Expensing Calculator 2026 — Free

Compare immediate R&D expensing under the OBBBA vs the old 5-year Section 174 amortization. See your year-1 cash flow advantage and total NPV benefit.

Total Section 174 research & experimental costs Please enter a valid amount.
Percentage of R&D conducted in the US Please enter a value between 0 and 100.
21% for C-corps; use individual rate for pass-throughs Please enter a valid rate.
Cost of capital or opportunity cost rate Please enter a valid rate.

Expensing vs Amortization Comparison

—
Year-1 Deduction (New: Immediate)
—
Year-1 Deduction (Old: Amortized)
—
Year-1 Tax Savings (New)
—
Year-1 Tax Savings (Old)
—
Cash Flow Advantage (Year 1)
—
NPV Advantage (Total)

The OBBBA restores immediate R&D expensing under Section 174, reversing the 2022 change that required businesses to amortize research expenses over 5 years (domestic) or 15 years (foreign).

How It Works

  1. Enter your total R&D expenses
  2. Set domestic R&D percentage
  3. Enter your marginal tax rate
  4. Review your cash flow and NPV advantage
Advertisement
728×90

R&D Expensing Under the OBBBA

The One Big Beautiful Bill Act (OBBBA) restores immediate, full expensing for research and experimental expenditures under Internal Revenue Code Section 174. This reverses a controversial change from the Tax Cuts and Jobs Act of 2017 (TCJA), which had required businesses to amortize R&D costs over 5 years (domestic) or 15 years (foreign) starting in 2022. The restoration of immediate expensing is one of the most significant business tax provisions in the OBBBA, affecting thousands of companies across technology, pharmaceuticals, manufacturing, and other R&D-intensive sectors.

What Changed

Before 2022, Section 174 allowed businesses to deduct research and experimental expenditures in full in the year they were incurred. The TCJA changed this for tax years beginning after December 31, 2021, requiring capitalization and amortization — 5 years for domestic R&D using the mid-year convention, and 15 years for foreign R&D. The OBBBA eliminates this amortization requirement and returns to immediate, 100% expensing. This change applies retroactively, and businesses that previously amortized R&D costs may be able to claim catch-up deductions.

Domestic vs Foreign R&D

Under the old amortization rules, the location of R&D activities mattered significantly. Domestic research (conducted within the United States) was amortized over 5 years with a mid-year convention, meaning only 10% was deductible in year one. Foreign research (conducted outside the US) faced an even steeper penalty: 15-year amortization with a mid-year convention, allowing only about 3.3% deduction in the first year. This calculator shows the amortization schedules for both scenarios so you can see the full cash-flow impact of the old rules compared to immediate expensing.

Cash Flow Impact

The difference in cash flow is substantial. Consider a company with $1 million in domestic R&D expenses at a 21% C-corp tax rate. Under immediate expensing, the company deducts the full $1 million in year one, saving $210,000 in federal taxes. Under the old 5-year amortization with mid-year convention, only $100,000 was deductible in year one (10%), saving just $21,000. That is a $189,000 cash flow advantage in the first year. Over time, the total deduction is the same — but the time value of money means immediate expensing is worth significantly more, which is captured in the NPV calculation. For a broader view of how R&D fits into your capital investment strategy, see our ROI calculator.

Who Benefits

C-corporations benefit at the flat 21% federal rate. Pass-through entities (S-corps, LLCs, partnerships, sole proprietors) benefit at the owner's individual marginal tax rate, which can range from 10% to 37%. Companies with large R&D budgets relative to revenue see the greatest cash flow improvement. Startups and growth-stage companies that previously faced cash crunches from the amortization requirement will find the most relief. The R&D tax credit under Section 41 remains available and can be stacked with full expensing — consult a tax professional about the interaction between the two provisions.

Amortization Schedule Comparison

YearOld Law (Domestic $500K)Old Law (Foreign $100K)New Law (Total $600K)
1$50,000$3,333$600,000
2$100,000$6,667—
3$100,000$6,667—
4$100,000$6,667—
5$100,000$6,667—
6$50,000$6,667—
7—$6,667—
8—$6,667—
9—$6,667—
10—$6,667—
11—$6,667—
12—$6,667—
13—$6,667—
14—$6,667—
15—$6,667—
16—$3,333—
For informational purposes only. This calculator provides estimates based on 2026 federal tax provisions under the OBBBA. R&D expenditures must qualify under Section 174. Consult a qualified tax professional before making financial decisions.

Frequently Asked Questions

What is R&D expensing under Section 174?
Section 174 of the Internal Revenue Code governs the tax treatment of research and experimental expenditures. Before 2022, businesses could immediately deduct R&D costs in the year incurred. The Tax Cuts and Jobs Act of 2017 changed this starting in 2022, requiring 5-year amortization for domestic R&D and 15-year amortization for foreign R&D. The OBBBA restores immediate expensing retroactively.
How does the OBBBA change R&D tax treatment?
The One Big Beautiful Bill Act (OBBBA) restores 100% immediate expensing for research and experimental expenditures under Section 174. Instead of amortizing R&D costs over 5 years (domestic) or 15 years (foreign), businesses can deduct the full amount in the year the expense is incurred. This applies retroactively and significantly improves cash flow for R&D-intensive companies.
What is the difference between domestic and foreign R&D?
Under the old amortization rules, domestic R&D (conducted within the United States) was amortized over 5 years using the mid-year convention, while foreign R&D (conducted outside the US) was amortized over 15 years. This made foreign R&D significantly more expensive on a present-value basis. Under the OBBBA, both domestic and foreign R&D qualify for immediate 100% expensing.
How does R&D expensing affect my cash flow?
Immediate expensing provides a much larger tax deduction in year one compared to amortization. For example, a company with $1 million in domestic R&D at a 21% tax rate saves $210,000 in year one under immediate expensing, versus only $21,000 under the old 5-year amortization (with mid-year convention). That is a $189,000 cash flow advantage in the first year alone.

Comments

Advertisement
728×90